Thus, our data propose a strong molecular rationale for the use of “drug holiday” in BRAF inhibitor regimes to bring about longer lasting clinical responses in V600EBRAF melanoma as suggested by Sun and colleagues [28]. Here, BRAF is linked to melanoma.